Voronoi Adds Thailand Regulatory Submission for VRN110755 Phase 1/2 Trial, Advancing Global Clinical Development
Voronoi disclosed that it has completed the submission of a clinical trial plan application to the Thailand FDA through an amendment to its material information regarding the Phase 1/2 study of VRN110755 in EGFR-mutant non-small cell lung cancer.
This amendment adds Thailand to the existing list of regulatory authorities including Taiwan, Australia, Singapore, Europe, and Malaysia, expanding the global clinical trial footprint.
The disclosure involves no capital changes or shareholder dilution, and any additional costs from the expansion will be covered by existing funds.
Clinical trial success probability is statistically approximately 10%, and investors should consider associated risks.
[AI Summary]Voronoi's addition of Thailand to its clinical trial plan is a routine step in advancing the pipeline, with no immediate financial impact. While the expansion is neutral in terms of capital allocation, it supports the drug's global development strategy. Shareholder value remains tied to future clinical data outcomes.
KOSDAQ Filing Information
[Correction of Description] Major Management Matters Related To Investment Decision (Application For Approval Of Clinical Trial Plan Change) (Phase 1/2 Clinical Trial Of VRN110755)